Zurich Insurance Group Ltd FI Takes Position in Kenvue Inc. (NYSE:KVUE)

Zurich Insurance Group Ltd FI acquired a new position in shares of Kenvue Inc. (NYSE:KVUE) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 91,600 shares of the company’s stock, valued at approximately $1,956,000.

Other hedge funds have also recently made changes to their positions in the company. Grove Bank & Trust boosted its position in shares of Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after buying an additional 947 shares during the period. Geneos Wealth Management Inc. acquired a new position in Kenvue during the 4th quarter worth about $29,000. SRS Capital Advisors Inc. boosted its holdings in Kenvue by 67.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after acquiring an additional 571 shares during the period. Asset Planning Inc purchased a new stake in Kenvue during the fourth quarter worth about $42,000. Finally, Clarity Asset Management Inc. acquired a new stake in shares of Kenvue during the fourth quarter worth about $45,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

KVUE has been the topic of several recent research reports. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $24.00 target price on shares of Kenvue in a research note on Monday, February 3rd. Evercore ISI began coverage on Kenvue in a research report on Monday, March 24th. They set an “in-line” rating and a $25.00 price objective on the stock. UBS Group lifted their target price on Kenvue from $24.00 to $25.00 and gave the company a “neutral” rating in a report on Friday, May 9th. Redburn Atlantic assumed coverage on Kenvue in a report on Thursday, April 10th. They set a “neutral” rating and a $23.50 price target on the stock. Finally, Citigroup lifted their price objective on Kenvue from $22.00 to $24.50 and gave the company a “neutral” rating in a research note on Friday, May 9th. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $25.33.

Kenvue Stock Performance

Shares of KVUE opened at $24.15 on Wednesday. The company has a market capitalization of $46.34 billion, a price-to-earnings ratio of 45.57, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $25.17. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The stock has a 50 day moving average price of $23.20 and a 200 day moving average price of $22.61.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.01. The business had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.69 billion. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. The company’s revenue was down 3.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.28 EPS. Research analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th will be paid a $0.205 dividend. The ex-dividend date is Wednesday, May 14th. This represents a $0.82 annualized dividend and a yield of 3.40%. Kenvue’s dividend payout ratio is presently 149.09%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.